Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by fuzzyjron Apr 02, 2019 10:07am

96 Views

Post# 29569141

RE:RE:RE:RE:RE:RE:RE:NR. RESVERLOGIX ANNOUNCES $15.1 in Private Placement

fyi : we closed up yesterday & today isnt over + we have months to go so steady as she goes. Watching dips or spkies daily in the SP will only cause one to stress. Waitng for the final data is what we all want ot see, the bumps & humps in between mean little right now IMO.

glta

Bullboard Posts

Maximizing savings: Exploring 5 cash-back and promo deal apps